2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Summary of changes.
作者信息
So Alan I, Saad Fred
机构信息
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Division of Urology, Department of Surgery, Université de Montréal, Montreal, QC, Canada.
出版信息
Can Urol Assoc J. 2022 Dec;16(12):389-391. doi: 10.5489/cuaj.8159.
Abstract
摘要
相似文献
1
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Summary of changes.2022年更新：加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌 变更摘要
Can Urol Assoc J. 2022 Dec;16(12):389-391. doi: 10.5489/cuaj.8159.
2
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.2022年更新：加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南：转移性去势初治和去势敏感性前列腺癌全文
Can Urol Assoc J. 2022 Dec;16(12):E581-E589. doi: 10.5489/cuaj.8148.
3
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
4
UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?更新 - 2021年加拿大泌尿外科协会（CUA）-加拿大泌尿肿瘤学组（CUOG）去势抵抗性前列腺癌（CRPC）指南：自2019年以来有哪些变化？
Can Urol Assoc J. 2021 Feb;15(2):11-12. doi: 10.5489/cuaj.7160.
5
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2019年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2019 Oct;13(10):307-314. doi: 10.5489/cuaj.6136.
6
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2021年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.
7
2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2022年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2022 Nov;16(11):E506-E515. doi: 10.5489/cuaj.8161.
8
Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.对于接受阿比特龙醋酸酯一线治疗的日本LATITUDE高危转移性去势敏感性前列腺癌患者，无进展生存期的有用预测指标。
Int J Urol. 2022 Mar;29(3):229-234. doi: 10.1111/iju.14754. Epub 2021 Dec 4.
9
A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association.加拿大在2019冠状病毒病大流行期间管理前列腺癌的框架：加拿大泌尿肿瘤学组和加拿大泌尿外科协会的建议
Can Urol Assoc J. 2020 Jun;14(6):163-168. doi: 10.5489/cuaj.6667.
10
Hong Kong Urological Association-Hong Kong Society of Uro-Oncology consensus statements on the management of advanced prostate cancer-2019 Updates.香港泌尿外科学会-香港泌尿肿瘤学会关于晚期前列腺癌管理的共识声明-2019 更新。
Asia Pac J Clin Oncol. 2021 Apr;17 Suppl 3:12-26. doi: 10.1111/ajco.13580.
本文引用的文献
1
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
2
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.达罗他胺与转移性去势敏感性前列腺癌的生存
**注**：这是基于你提供的文本进行的翻译，实际翻译可能会因上下文和语言习惯而有所不同。
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
3
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.真实世界中雄激素剥夺治疗的应用：加拿大初发转移性前列腺癌老年男性中的强化治疗。
JNCI Cancer Spectr. 2021 Oct 1;5(6). doi: 10.1093/jncics/pkab082. eCollection 2021 Dec.
4
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States.美国真实世界中转移性前列腺癌男性患者的全身治疗模式及疗效
Cancers (Basel). 2021 Sep 30;13(19):4951. doi: 10.3390/cancers13194951.
5
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
6
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
Zotero 插件